Viewing Study NCT06568692


Ignite Creation Date: 2025-12-24 @ 3:25 PM
Ignite Modification Date: 2026-01-28 @ 5:03 AM
Study NCT ID: NCT06568692
Status: RECRUITING
Last Update Posted: 2025-06-19
First Post: 2024-08-21
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Sponsor: Processa Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module